List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
16 July 2018 | By Catherine Lautenschlager (PerkinElmer), Hong Cao (PerkinElmer)
AlphaLISA® provides a robust assay that facilitates the design and development of antibody therapeutics.
11 July 2018 | By IDBS
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
22 June 2018 | By Drug Target Review
Addressing the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation...
15 June 2018 | By IntelliCyt
The Intellicyt Mouse IgG Type and Titer Kit is a high throughput, multiplexed assay kit that enables analyses of isotype, titer and cell health in a single assay...
15 June 2018 | By IntelliCyt Corporation
Analyse isotype titer and cell health in one assay...
14 June 2018 | By Drug Target Review
The administration of silibinin in patients with brain metastasis reduces lesions without causing any adverse effects, according to a study led by researchers at the Spanish National Cancer Research Centre (CNIO).
13 June 2018 | By Drug Target Review
Scientists have deployed a novel genetic screen to search for synthetic viable interactions on special lines of Fanconi Anaemia-defective cells...
11 June 2018 | By PerkinElmer
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
8 June 2018 | By Tecan
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
7 June 2018 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)
For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.
6 June 2018 | By Joseph Zock (Senior Director - Product Management - IntelliCyt -a Sartorius Company)
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
6 June 2018 | By PerkinElmer
High-content assays using 3D objects, such as cysts or organoids, can be challenging from the perspectives of both image acquisition and image analysis.
6 June 2018 | By Sesha Tekur (Key Accounts Manage/Field Application Specialist at Thermo Fisher Scientific)
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
5 June 2018 | By Philip Spencer (AstraZeneca)
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
5 June 2018 | By Thermo Fisher Scientfic
Introducing the Thermo Scientific™ CellInsight™ CX7 LZR High Content Analysis System: the only imaging and analysis platform for advanced performance in screening and analysis.
Send this to a friend
Follow: